Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ELAN RIGHTS OFFERING COULD RAISE UP TO $78 MIL. FOR PANODERM

This article was originally published in The Gray Sheet

Executive Summary

ELAN RIGHTS OFFERING COULD RAISE UP TO $78 MIL. FOR PANODERM and other drug delivery system projects. The company is returning to the fundraising technique it used in 1990 when it set up the Drug Research Corporation as a funding vehicle for the early stage development of its ETDAS (Electro-Transport Drug Administration System) and IPDAS (Intestinal Protective Drug Absorption System) technologies. This time, Elan is proposing the sale of 3.9 mil. units of Advanced Therapeutic Systems to raise additional cash for development and commercialization of ETDAS and two other proprietary technologies. ETDAS technology facilitates the controlled administration of drugs under the influence of low-powered electrical stimulus. Elan's Panoderm and Panoject delivery devices both incorporate ETDAS technology. A spokesperson said that Panoderm, a watch-like device used for transdermal delivery of peptides, narcotics and cardiovascular drugs, has completed Phase II trials and will soon advance to Phase III. In its second quarter report for fiscal year 1993 (year ending March 31), Elan said it expects to file for approval of Panoject "in the current fiscal year." The other two drug delivery projects that ATS would fund are still in the early stages of development. BEODAS (Biodegradable Enhanced Oral Drug Administration System) provides a method of entrapping drug substances for enhanced oral release that may apply to a range of products, including peptide and hormone products, the company reports. MIDAS (Microparticle Injectable Drug Administration System) technology applies to long-acting injections; by adjusting the release characteristic of a drug, the technology may allow for pulsating drug delivery to correspond with natural hormone cycles. Elan is evaluating a range of products for MIDAS technology, focusing particularly on hormones and hormone replacement systems. Elan/ATS filed a registration statement June 2 with the Securities and Exchange Commission for the proposed sale of the units at an expected subscription price of $20 apiece. Each unit will consist of one share of common stock of ATS and one five-year warrant to acquire an Elan American depository share. Holders of Elan American depository shares and Elan ordinary shares will receive one right for each share owned as of the record date for distribution of the rights. Eight rights will be required to subscribe to one unit, Elan said. Rights holders will be entitled to subscribe to any additional units that may be available as a result of rights expiring without exercise. The offering will be withdrawn if the aggregate gross proceeds of subscriptions fall short of $45 mil. In addition to the net proceeds from the offering, ATS will receive an additional $25 mil. from Elan upon its consummation. The funds will be used to make payments to Elan under an R&D agreement. Elan and ATS each will have certain licensing rights with respect to the products being developed, and Elan will have the option to acquire all of the common stock of ATS during a specified time period in the future.

You may also be interested in...



Surging China Coronavirus Trials Prompt Tougher Criteria

A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules. 

Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag

Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.

Bayer Consumer Health Recovery Rides Allergy, Dermatology Brand Sales

Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.
UsernamePublicRestriction

Register

MT000710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel